Ribonucleoside 3'-phosphates as pro-moieties for an orally administered drug.
作者信息
Palte Michael J, Davis Amy K F, McGrath Nicholas A, Spiegel Carol A, Raines Ronald T
机构信息
Medical Scientist Training Program and Molecular & Cellular Pharmacology Graduate Training Program, University of Wisconsin-Madison, 750 Highland Avenue, Madison, WI 53705, USA.
出版信息
ChemMedChem. 2012 Aug;7(8):1361-4. doi: 10.1002/cmdc.201200243. Epub 2012 Jul 13.
Abstract
摘要
相似文献
1
Ribonucleoside 3'-phosphates as pro-moieties for an orally administered drug.
ChemMedChem. 2012 Aug;7(8):1361-4. doi: 10.1002/cmdc.201200243. Epub 2012 Jul 13.
2
Mechanisms of Bacteroides fragilis resistance to metronidazole.
Infect Genet Evol. 2018 Oct;64:156-163. doi: 10.1016/j.meegid.2018.06.020. Epub 2018 Jun 21.
3
Bacteroides fragilis resistant to metronidazole after long-term therapy.
Lancet. 1978 Jan 28;1(8057):214. doi: 10.1016/s0140-6736(78)90655-4.
4
Bacteraemia due to Bacteroides fragilis with reduced susceptibility to metronidazole.
J Antimicrob Chemother. 2003 Jun;51(6):1436-7. doi: 10.1093/jac/dkg265. Epub 2003 May 13.
5
Enhanced pathogenicity of susceptible strains of the Bacteroides fragilis group subjected to low doses of metronidazole.
Microbes Infect. 2003 Jan;5(1):19-26. doi: 10.1016/s1286-4579(02)00052-7.
6
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2005 Feb;49(2):685-9. doi: 10.1128/AAC.49.2.685-689.2005.
7
Metronidazole resistant Bacteroides fragilis infection of a prosthetic hip joint.
J Infect. 1990 Mar;20(2):129-33. doi: 10.1016/0163-4453(90)93340-x.
8
The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
Anaerobe. 2017 Feb;43:1-3. doi: 10.1016/j.anaerobe.2016.09.008. Epub 2016 Oct 3.
9
[Bacteriological and clinical studies on metronidazole in Bacteroides fragilis infections (author's transl)].
Jpn J Antibiot. 1979 Feb;32(2):191-4.
10
Bacteroides fragilis meningitis successfully treated with metronidazole after a previous failure with thiamphenicol.
J Clin Microbiol. 1986 Sep;24(3):472-3. doi: 10.1128/jcm.24.3.472-473.1986.
引用本文的文献
1
Metal-free visible-light-promoted C(sp)-H functionalization of aliphatic cyclic ethers using trace O.
Green Chem. 2021 Dec 7;23(23):9454-9459. doi: 10.1039/d1gc03482k. Epub 2021 Nov 5.
2
Prodrugs of phosphonates and phosphates: crossing the membrane barrier.
Top Curr Chem. 2015;360:115-60. doi: 10.1007/128_2014_561.
本文引用的文献
1
Ribonuclease-Activated Cancer Prodrug.
ACS Med Chem Lett. 2012 Feb 28;3(4):268-272. doi: 10.1021/ml2002554.
2
Oral drug delivery systems comprising altered geometric configurations for controlled drug delivery.
Int J Mol Sci. 2012;13(1):18-43. doi: 10.3390/ijms13010018. Epub 2011 Dec 22.
3
Rational design and evaluation of mammalian ribonuclease cytotoxins.
Methods Enzymol. 2012;502:273-90. doi: 10.1016/B978-0-12-416039-2.00014-8.
4
Microfabricated particulate drug-delivery systems.
Biotechnol J. 2011 Dec;6(12):1477-87. doi: 10.1002/biot.201100237. Epub 2011 Nov 11.
5
A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds.
Curr Pharm Des. 2011;17(32):3515-26. doi: 10.2174/138161211798194512.
6
Bovine pancreatic ribonuclease: fifty years of the first enzymatic reaction mechanism.
Biochemistry. 2011 Sep 20;50(37):7835-41. doi: 10.1021/bi201075b. Epub 2011 Aug 24.
7
Applications of polymeric nanocapsules in field of drug delivery systems.
Curr Drug Discov Technol. 2011 Sep;8(3):173-87. doi: 10.2174/157016311796799008.
8
Critical factors in the release of drugs from sustained release hydrophilic matrices.
J Control Release. 2011 Aug 25;154(1):2-19. doi: 10.1016/j.jconrel.2011.04.002. Epub 2011 Apr 8.
9
Value of general Acid-base catalysis to ribonuclease a.
J Am Chem Soc. 1994 Jun;116(12):5467-8. doi: 10.1021/ja00091a060.
10
Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
Curr Med Chem. 2010;17(32):3874-908. doi: 10.2174/092986710793205426.
Zotero 插件